HomeAboutScientific TeamCode of Good PracticeResearchCOVID-19 TestingCardiac HealthClinical Trial Design & MethodologyHepatologyEthnic and Sex Differences Physiology & Drug ResponsesPublicationsNewsCareersSupportContact

What’s a Rich Text element? (H1)

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

What’s a Rich Text element? (H2)

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing (H3)

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text (H4)

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

How to customize formatting for each rich text (H5)

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

How to customize formatting for each rich text (H6)

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

  • Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
  • Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
  • Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

AHA Scientific Sessions 2025

8 - 10 November 2025

Richmond Pharmacology is excited to confirm our attendance at AHA Scientific Sessions 2025, hosted by the American Heart Association in New Orleans from 8–10 November.

Representing Richmond at AHA 2025:

  • Dr Jörg Täubel, Chief Executive Officer
  • James Rickard, Chief Scientific Officer

We look forward to connecting with attendees to discuss Richmond’s expertise in:

  • Early-phase cardiovascular and cardiometabolic research
  • First-in-human and dose-ranging studies
  • Novel biomarkers and digital endpoints
  • Regulatory engagement and global trial delivery
  • Patient-first strategies in complex CV trials

If you’re attending AHA 2025 and seeking a clinical development partner with cardiovascular expertise, arrange a meeting with us: info@richmondpharmacology.com

Learn more: AHA 2025 | American Heart Association's Scientific Sessions

Related News

HFA 2025

Richmond Research Institute to present key cardiology research at Heart Failure 2025 in Belgrade, Serbia.

First patient enrolled in telehealth study, the Pathway Study

The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and...

Characterisation of the Cardiovascular Effects of a Meal: QTcF Assessment and Further Insights into the Physiological Effects

Authored by Georg Ferber, PhD, Dilshat Djumanov, PhD, Ulrike Lorch, MD, FFPM, Edward Jackson, BSc, MSc, PhD, MBChB, Joao Almeida Melo, James Rickard, MPharm, and Jorg Taubel, MD, FFPM, FESC.

Dr Dominic Pimenta wins the 'Young Investigators Award for Primary Care and Risk Factor Management'

RRI Lead Specialty Research Physician wins award for Cardiovascular risk factor analysis of data associated with UK grocery brand Tescos

RRI study finds antimalaria drug has no negative impact on cardiac safety in healthy volunteers

We studied the cardiac safety of P218 using advanced QTc assessments and found doses of up to 1000mg do not prolong the QTc suggesting a low risk of drug induced arrhythmia.

Phase I study confirms cardiac safety of potential alopecia treatment

Here we present the results of our recent work on the cardiac safety of cortexolone 17α-propionate (cortexolone).

Effectiveness of 12-lead ECG versus Holter monitor confirmed in important trial methodology

12-lead resting ECGs are considered essential in clinical trials, but their limitations have led to increasing use of 12-lead Holter monitor devices.

Cardiac safety of nolasiban confirmed in Phase I clinical trial

Here we report our recent work on the cardiac safety of nolasiban.

Why more caution is needed in administering QT prolonging drugs to type 1 diabetic patients.

Findings from our recent study show how cardiac ion channel blocking agents could increase the risk of sudden cardiac death in patients with type 1 diabetes, particularly in women.

Back to News